Home > Insider Trading > Filing (0001179110-11-003364)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235010	Momenta Pharmaceuticals Inc	MNTA	Biological Products, (No Disgnostic Substances) (2836)	043561634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1308911	E John Bishop	675 West Kendall Street Cambridge MA 02142	Senior Vp, Pharmaceutical Scie	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2011-02-22	1,185	$13.45	45,472	No	4	S	Direct
Common Stock	Acquisiton	2011-02-22	10,198	$0.00	55,670	No	4	A	Direct
Common Stock	Disposition	2011-02-23	308	$13.26	55,362	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2011-02-22	25,495	$0.00	25,495	$13.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
142,359	2011-05-22	2021-02-22	No	4	A	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2009.
Represents 10,198 shares of restricted common stock, $0.0001 par value per share, awarded pursuant to the Company's 2004 Stock Incentive Plan, as amended, and subject to a restricted stock agreement to be entered into between the Company and Mr. Bishop. Pursuant to the restricted stock agreement, 25% of the shares of restricted Common Stock shall vest on February 22, 2012, and an additional 6.25% of the shares of restricted Common Stock shall vest at the end of each three-month period thereafter.
Represents an option granted by the issuer pursuant to the issuer's 2004 Stock Incentive Plan. Subject to certain criteria, the shares subject to such option vest as to 6.25% of the shares at the end of each three-month period following the grant date.